CHERRY ANTISEPTIC THROAT LOZENGES 2.4MG/LOZ 2.4 MG
HEXYLRESORCINOL : 2.4 MG · DIN 01996797 · KSL PHARMACEUTICALS
Health Canada status: CANCELLED POST MARKET
What is CHERRY ANTISEPTIC THROAT LOZENGES 2.4MG/LOZ?
CHERRY ANTISEPTIC THROAT LOZENGES 2.4MG/LOZ 2.4 MG contains HEXYLRESORCINOL : 2.4 MG. It is listed in the Health Canada Drug Product Database under DIN 01996797, held by KSL PHARMACEUTICALS, supplied as LOZENGE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 09-Sep-1996. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 01996797 |
|---|---|
| Brand name | CHERRY ANTISEPTIC THROAT LOZENGES 2.4MG/LOZ |
| Generic / active ingredient | HEXYLRESORCINOL : 2.4 MG |
| Manufacturer | KSL PHARMACEUTICALS |
| Strength | 2.4 MG |
| Dosage form | LOZENGE |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | R02AA12 HEXYLRESORCINOL |
| AHFS class | 52:04.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 09-Sep-1996 |
| Original market date | 1994-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code R02AA12 HEXYLRESORCINOL. 3 of 26 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BRADOSOL LOZENGES EXTRA STRENGTH 3.5MG | 3.5 MG | LOZENGE | COLUMBIA LABORATORIES CANADA INC | MARKETED | DIN 00895466 |
| STREPSILS ANAESTHETIC FORMULA | 2.4 MG | LOZENGE | RB HEALTH (CANADA) INC. | MARKETED | DIN 02243888 |
| STREPSILS EXTRA BLACK CHERRY | 2.4 MG | LOZENGE | RB HEALTH (CANADA) INC. | MARKETED | DIN 02263998 |
| ANTISEPTIC SORE THROAT LOZ. (LEMON FLAVOUR) | 2.4 MG | LOZENGE | H.J. SUTTON INDUSTRIES LTD. | CANCELLED POST MARKET | DIN 02227568 |
| ANTISEPTIC SORE THROAT LOZ(HONEY EUCALYP.FL) | 2.4 MG | LOZENGE | H.J. SUTTON INDUSTRIES LTD. | CANCELLED POST MARKET | DIN 02227541 |
| ANTISEPTIC SORE THROAT LOZ(MINT MENTHOL FLV) | 2.4 MG | LOZENGE | H.J. SUTTON INDUSTRIES LTD. | CANCELLED POST MARKET | DIN 02228424 |
| ANTISEPTIC THROAT LOZENGES (WITH HEXYLRESORCINOL) | 2.4 MG | LOZENGE | H.J. SUTTON INDUSTRIES LTD. | CANCELLED POST MARKET | DIN 02228432 |
| BRADOSOL LOZENGES EXTRA STRENGTH 3.5MG MINT | 3.5 MG | LOZENGE | COLUMBIA LABORATORIES CANADA INC | DORMANT | DIN 00894214 |
| BRADOSOL LOZENGES REGULAR STRENGTH 2.4MG (CHERRY, MINT, LEMON, ORANGE, HONEY-EUCALYPTUS) | 2.4 MG | LOZENGE | COLUMBIA LABORATORIES CANADA INC | DORMANT | DIN 00846589 |
| BRADOSOL MULTIFLAVOUR LOZ 2.4MG | 2.4 MG | LOZENGE | CIBA SELF MEDICATION | CANCELLED POST MARKET | DIN 01919148 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.